[P02BB01, trichlorfon, The therapeutic efficacy of Metrifonate can be decreased when used in combination with Methylprednisolone aceponate.]
[S02DA03, antipyrine, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Antipyrine.]
[A14AA02, stanozolol, The risk or severity of fluid retention can be increased when Methylprednisolone aceponate is combined with Stanozolol.]
[G03XB02, ulipristal, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Ulipristal.]
[M03AB01, succinylcholine, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Methylprednisolone aceponate.]
[J01EC02, sulfadiazine, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Sulfamethoxazole.]
[S01AB02, sulfisoxazole, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Sulindac.]
[N05AL01, sulpiride, The therapeutic efficacy of Sulpiride can be decreased when used in combination with Methylprednisolone aceponate.]
[A10BB04, glibornuride, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Azapropazone.]
[N06DA01, tacrine, The therapeutic efficacy of Tacrine can be decreased when used in combination with Methylprednisolone aceponate.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Methylprednisolone aceponate.]
[G03BA03, testosterone, The risk or severity of edema formation can be increased when Testosterone is combined with Methylprednisolone aceponate.]
[L01AC01, thiotepa, The therapeutic efficacy of Thiotepa can be decreased when used in combination with Methylprednisolone aceponate.]
[B02AB01, aprotinin, The therapeutic efficacy of Aprotinin can be decreased when used in combination with Methylprednisolone aceponate.]
[A10BB05, tolazamide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Tolazamide.]
[V04CA01, tolbutamide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Tolmetin.]
[C03AA06, trichlormethiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone aceponate is combined with Trichlormethiazide.]
[S01EB04, demecarium, The therapeutic efficacy of Demecarium can be decreased when used in combination with Methylprednisolone aceponate.]
[N05AA05, triflupromazine, The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Methylprednisolone aceponate.]
[M03AA02, tubocurarine, The therapeutic efficacy of Tubocurarine can be decreased when used in combination with Methylprednisolone aceponate.]
[S01AA05, tyrothricin, The therapeutic efficacy of Tyrothricin can be decreased when used in combination with Methylprednisolone aceponate.]
[A10BH05, linagliptin, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Linagliptin.]
[R03AC18, indacaterol, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Indacaterol.]
[B01AA03, warfarin, Methylprednisolone aceponate may increase the anticoagulant activities of Warfarin.]
[H05BX03, doxercalciferol, The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Methylprednisolone aceponate.]
[J01MA13, trovafloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Trovafloxacin.]
[G03AC10, drospirenone, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Drospirenone.]
[N02BA01, aspirin, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Acetylsalicylic acid.]
[A11CC03, alfacalcidol, The therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Methylprednisolone aceponate.]
[J02AC03, voriconazole, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of myopathy and weakness can be increased when Atracurium is combined with Methylprednisolone aceponate.]
[A02AA05, magnesium silicate, The bioavailability of Methylprednisolone aceponate can be decreased when combined with Magnesium silicate.]
[A02AC02, calcium silicate, The bioavailability of Methylprednisolone aceponate can be decreased when combined with Calcium silicate.]
[C01AA01, acetyldigitoxin, The risk or severity of adverse effects can be increased when Methylprednisolone aceponate is combined with Acetyldigitoxin.]
[N06DA02, donepezil, The therapeutic efficacy of Donepezil can be decreased when used in combination with Methylprednisolone aceponate.]
[A10BH04, alogliptin, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, The therapeutic efficacy of Glycerol phenylbutyrate can be decreased when used in combination with Methylprednisolone aceponate.]
[C03AA01, bendroflumethiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone aceponate is combined with Bendroflumethiazide.]
[N02BA10, benorilate, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Benorilate.]
[A10BK02, canagliflozin, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Moxifloxacin.]
[A10AE05, insulin detemir, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin detemir.]
[A10BX05, pramlintide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Pramlintide.]
[M01AH01, celecoxib, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Celecoxib.]
[R02AX03, benzydamine, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Benzydamine.]
[A10BJ03, lixisenatide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Lixisenatide.]
[G03AC08, etonogestrel, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Etonogestrel.]
[A10BK01, dapagliflozin, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Dapagliflozin.]
[C01CA27, droxidopa, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Droxidopa.]
[L02BG02, formestane, The risk or severity of edema formation can be increased when Formestane is combined with Methylprednisolone aceponate.]
[A16AA06, betaine, The therapeutic efficacy of Betaine can be decreased when used in combination with Methylprednisolone aceponate.]
[A10BJ04, albiglutide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Albiglutide.]
[L01ED02, ceritinib, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Ceritinib.]
[B01AA07, acenocoumarol, Methylprednisolone aceponate may increase the anticoagulant activities of Acenocoumarol.]
[A10BK03, empagliflozin, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Olodaterol.]
[V04CX03, methacholine, Methylprednisolone aceponate may decrease effectiveness of Methacholine as a diagnostic agent.]
[A10BJ05, dulaglutide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Dulaglutide.]
[B01AA01, dicumarol, Methylprednisolone aceponate may increase the anticoagulant activities of Dicoumarol.]
[B01AA11, tioclomarol, Methylprednisolone aceponate may increase the anticoagulant activities of Tioclomarol.]
[A06AD03, magnesium peroxide, The bioavailability of Methylprednisolone aceponate can be decreased when combined with Magnesium peroxide.]
[A10BF01, acarbose, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Acarbose.]
[M02AA25, aceclofenac, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Acemetacin.]
[A10AE06, insulin degludec, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin degludec.]
[A10BB31, acetohexamide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Acetohexamide.]
[M01AE16, alminoprofen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Alminoprofen.]
[A02AB06, aloglutamol, The bioavailability of Methylprednisolone aceponate can be decreased when combined with Aloglutamol.]
[N04BC01, bromocriptine, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, The bioavailability of Methylprednisolone aceponate can be decreased when combined with Almasilate.]
[A02AB03, aluminum phosphate, The bioavailability of Methylprednisolone aceponate can be decreased when combined with Aluminium phosphate.]
[C03CA02, bumetanide, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Bumetanide.]
[N06DA03, rivastigmine, The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Methylprednisolone aceponate.]
[J01MA09, sparfloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Sparfloxacin.]
[A07EC04, balsalazide, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Balsalazide.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Methylprednisolone aceponate.]
[A10BX06, benfluorex, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Benfluorex.]
[H05BX05, calcifediol, The therapeutic efficacy of Calcifediol can be decreased when used in combination with Methylprednisolone aceponate.]
[D05AX03, calcitriol, The therapeutic efficacy of Calcitriol can be decreased when used in combination with Methylprednisolone aceponate.]
[A12AA04, calcium carbonate, The bioavailability of Methylprednisolone aceponate can be decreased when combined with Calcium carbonate.]
[J01MA23, delafloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Delafloxacin.]
[R03AC17, bitolterol, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Bitolterol.]
[M01AB07, bumadizone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Bumadizone.]
[C01AA02, acetyldigoxins, The risk or severity of adverse effects can be increased when Methylprednisolone aceponate is combined with Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Semaglutide.]
[N01BX04, capsaicin, The therapeutic efficacy of Capsaicin can be decreased when used in combination with Methylprednisolone aceponate.]
[A10BK04, ertugliflozin, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Ertugliflozin.]
[C07AB08, celiprolol, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Celiprolol.]
[A10BB06, carbutamide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Carbutamide.]
[M01AC05, lornoxicam, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Lornoxicam.]
[C03AA09, cyclothiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone aceponate is combined with Cyclothiazide.]
[A10AE03, insulin, regular, pork, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin pork.]
[G03DB05, demegestone, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Demegestone.]
[G03AC09, desogestrel, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Desogestrel.]
[S01XA12, dexpanthenol, The therapeutic efficacy of Dexpanthenol can be decreased when used in combination with Methylprednisolone aceponate.]
[S01AE06, gatifloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Gatifloxacin.]
[G03DB08, dienogest, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Dienogest.]
[M01AH02, rofecoxib, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Rofecoxib.]
[M01AC04, droxicam, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Droxicam.]
[M02AA27, dexketoprofen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Dexketoprofen.]
[C03AA04, chlorothiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone aceponate is combined with Chlorothiazide.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Methylprednisolone aceponate.]
[A10BB02, chlorpropamide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Chlorpropamide.]
[C03BA04, chlorthalidone, Methylprednisolone aceponate may increase the hypokalemic activities of Chlorthalidone.]
[A11CC05, cholecalciferol, The therapeutic efficacy of Cholecalciferol can be decreased when used in combination with Methylprednisolone aceponate.]
[N02BA07, ethenzamide, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Ethenzamide.]
[C10AC01, cholestyramine resin, Cholestyramine may increase the excretion rate of Methylprednisolone aceponate which could result in a lower serum level and potentially a reduction in efficacy.]
[G03DC06, ethynodiol, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Etynodiol.]
[M01AB08, etodolac, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Etofenamate.]
[M01AE05, fenbufen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Fenbufen.]
[J01MB07, flumequine, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Flumequine.]
[R03CC15, formoterol, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Formoterol.]
[A10AF01, insulin, regular, human, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin human.]
[J01MB06, cinoxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Ciprofloxacin.]
[L01XA01, cisplatin, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Methylprednisolone aceponate.]
[A10BB12, glimepiride, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Glimepiride.]
[A10BB08, gliquidone, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Gliquidone.]
[R03CC13, clenbuterol, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Clenbuterol.]
[A10BX16, tirzepatide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Tirzepatide.]
[A10BX01, guar gum, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Sotagliflozin.]
[M01AX13, proquazone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Proquazone.]
[M03AC05, hexafluorenium, The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Methylprednisolone aceponate.]
[A02AD04, hydrotalcite, The bioavailability of Methylprednisolone aceponate can be decreased when combined with Hydrotalcite.]
[A10BX03, nateglinide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Mecasermin.]
[A10AE04, insulin glargine, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin glargine.]
[B01AC10, indobufen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Indobufen.]
[M01AH03, valdecoxib, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Valdecoxib.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methylprednisolone aceponate.]
[C01AA06, lanatoside C, The risk or severity of adverse effects can be increased when Methylprednisolone aceponate is combined with Lanatoside C.]
[M01AH04, parecoxib, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Parecoxib.]
[M01AA06, kebuzone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Kebuzone.]
[S01AE04, lomefloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Loxoprofen.]
[A02AD02, magaldrate, The bioavailability of Methylprednisolone aceponate can be decreased when combined with Magaldrate.]
[A06AD01, magnesium carbonate, The bioavailability of Methylprednisolone aceponate can be decreased when combined with Magnesium carbonate.]
[C03AA07, cyclopenthiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone aceponate is combined with Cyclopenthiazide.]
[A10BF02, miglitol, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Miglitol.]
[N06AX07, minaprine, The therapeutic efficacy of Minaprine can be decreased when used in combination with Methylprednisolone aceponate.]
[S01XA18, cyclosporine, The risk or severity of adverse effects can be increased when Methylprednisolone aceponate is combined with Cyclosporine.]
[M02AA02, mofebutazone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Morniflumate.]
[M01AH05, etoricoxib, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Etoricoxib.]
[G03XA01, danazol, The risk or severity of fluid retention can be increased when Methylprednisolone aceponate is combined with Danazol.]
[M01AX01, nabumetone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Nabumetone.]
[C01DX16, nicorandil, The risk or severity of ulceration can be increased when Methylprednisolone aceponate is combined with Nicorandil.]
[G03DB04, nomegestrol, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Nomegestrol.]
[M03AC11, cisatracurium, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Methylprednisolone aceponate.]
[A07EC03, olsalazine, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Olsalazine.]
[C01AA07, deslanoside, The risk or severity of adverse effects can be increased when Methylprednisolone aceponate is combined with Deslanoside.]
[M01AE12, oxaprozin, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Oxaprozin.]
[S02DA04, dibucaine, The therapeutic efficacy of Cinchocaine can be decreased when used in combination with Methylprednisolone aceponate.]
[S01BC03, diclofenac, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Diclofenac.]
[A10BG03, pioglitazone, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Pioglitazone.]
[R03CC07, pirbuterol, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Pirbuterol.]
[C03CA03, piretanide, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Piretanide.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Diethylcarbamazine can be decreased when used in combination with Methylprednisolone aceponate.]
[L02AA01, diethylstilbestrol, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Diethylstilbestrol.]
[N02BA11, diflunisal, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of adverse effects can be increased when Methylprednisolone aceponate is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of adverse effects can be increased when Methylprednisolone aceponate is combined with Digoxin.]
[A11CC02, dihydrotachysterol, The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Methylprednisolone aceponate.]
[R03CC08, procaterol, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Procaterol.]
[N02BB04, propyphenazone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Proglumetacin.]
[C01BA03, disopyramide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Disopyramide.]
[N07AA03, distigmine, The therapeutic efficacy of Distigmine can be decreased when used in combination with Methylprednisolone aceponate.]
[J01MB01, rosoxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Sunitinib.]
[S01BC05, ketorolac, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Ketorolac.]
[N02BA06, salsalate, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Dobutamine.]
[B05XA02, sodium bicarbonate, The bioavailability of Methylprednisolone aceponate can be decreased when combined with Sodium bicarbonate.]
[V04CX07, edrophonium, The therapeutic efficacy of Edrophonium can be decreased when used in combination with Methylprednisolone aceponate.]
[J01MA05, temafloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Temafloxacin.]
[M01AC02, tenoxicam, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Tenoxicam.]
[M01AG02, tolfenamic acid, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Tolfenamic acid.]
[C03CA04, torsemide, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Torasemide.]
[H02CA01, trilostane, The risk or severity of edema formation can be increased when Trilostane is combined with Methylprednisolone aceponate.]
[J01MA04, enoxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Enoxacin.]
[S01FB02, ephedrine, Ephedrine may increase the excretion rate of Methylprednisolone aceponate which could result in a lower serum level and potentially a reduction in efficacy.]
[S01EA01, epinephrine, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Epinephrine.]
[M01AB04, zomepirac, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Zomepirac.]
[A10AB06, insulin glulisine, human, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin glulisine.]
[A11CC01, ergocalciferol, The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Methylprednisolone aceponate.]
[G03CA03, estradiol, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Estradiol.]
[L02AA03, ethinyl estradiol, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Ethinylestradiol.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Methylprednisolone aceponate.]
[M01AC06, meloxicam, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Meloxicam.]
[A02BA04, nizatidine, The therapeutic efficacy of Nizatidine can be decreased when used in combination with Methylprednisolone aceponate.]
[J01MA08, fleroxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Fleroxacin.]
[M01AE04, fenoprofen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Fenoprofen.]
[R03CC04, fenoterol, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Fenoterol.]
[R03CC02, albuterol, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Salbutamol.]
[N02BG04, floctafenine, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Floctafenine.]
[G03BA01, fluoxymesterone, The risk or severity of fluid retention can be increased when Methylprednisolone aceponate is combined with Fluoxymesterone.]
[S01BC04, flurbiprofen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Flurbiprofen.]
[M03AA01, alcuronium, The risk or severity of myopathy and weakness can be increased when Alcuronium is combined with Methylprednisolone aceponate.]
[C03CA01, furosemide, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Furosemide.]
[N06DA04, galantamine, The therapeutic efficacy of Galantamine can be decreased when used in combination with Methylprednisolone aceponate.]
[M03AC02, gallamine, The risk or severity of myopathy and weakness can be increased when Gallamine is combined with Methylprednisolone aceponate.]
[A10BJ02, liraglutide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Liraglutide.]
[G03XA02, gestrinone, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Gestrinone.]
[A10BB01, glyburide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Glyburide.]
[A10BB09, gliclazide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Glipizide.]
[B01AA12, fluindione, Methylprednisolone aceponate may increase the anticoagulant activities of Fluindione.]
[A10AD05, insulin aspart, human, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin aspart.]
[A07EC02, mesalamine, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Mesalazine.]
[R03CC05, hexoprenaline, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Hexoprenaline.]
[M02AA26, nimesulide, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Nimesulide.]
[C03AA03, hydrochlorothiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone aceponate is combined with Hydrochlorothiazide.]
[C03AA02, hydroflumethiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone aceponate is combined with Hydroflumethiazide.]
[R02AX02, ibuprofen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Ibuprofen.]
[C03BA11, indapamide, Methylprednisolone aceponate may increase the hypokalemic activities of Indapamide.]
[S01BC01, indomethacin, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Indomethacin.]
[A10BH01, sitagliptin, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Sitagliptin.]
[A10BH02, vildagliptin, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Vildagliptin.]
[C03BA02, quinethazone, Methylprednisolone aceponate may increase the hypokalemic activities of Quinethazone.]
[R03CC06, isoetharine, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Isoetharine.]
[S01EB07, isoflurophate, The therapeutic efficacy of Isoflurophate can be decreased when used in combination with Methylprednisolone aceponate.]
[J04AC01, isoniazid, The serum concentration of Isoniazid can be decreased when it is combined with Methylprednisolone aceponate.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Methylprednisolone aceponate.]
[A10BJ01, exenatide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Exenatide.]
[A02AB01, aluminum hydroxide, The bioavailability of Methylprednisolone aceponate can be decreased when combined with Aluminum hydroxide.]
[N01AX03, ketamine, The therapeutic efficacy of Ketamine can be decreased when used in combination with Methylprednisolone aceponate.]
[M02AA10, ketoprofen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Ketoprofen.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal ulceration and gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Deferasirox.]
[C01CA22, arbutamine, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Arbutamine.]
[M01AE11, tiaprofenic acid, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Tiaprofenic acid.]
[C03CC01, ethacrynic acid, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Etacrynic acid.]
[J01MB04, pipemidic acid, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Pipemidic acid.]
[M01AG01, mefenamic acid, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Mefenamic acid.]
[J01MB02, nalidixic acid, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Nalidixic acid.]
[N07AA30, ambenonium, The therapeutic efficacy of Ambenonium can be decreased when used in combination with Methylprednisolone aceponate.]
[G03AD01, levonorgestrel, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Levonorgestrel.]
[G03DC03, lynestrenol, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Lynestrenol.]
[G04BX01, magnesium hydroxide, The bioavailability of Methylprednisolone aceponate can be decreased when combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The bioavailability of Methylprednisolone aceponate can be decreased when combined with Magnesium oxide.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Mechlorethamine can be decreased when used in combination with Methylprednisolone aceponate.]
[M02AA18, meclofenamic acid, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Meclofenamic acid.]
[C01AA08, medigoxin, The risk or severity of adverse effects can be increased when Methylprednisolone aceponate is combined with Metildigoxin.]
[P01BC02, mefloquine, The therapeutic efficacy of Mefloquine can be decreased when used in combination with Methylprednisolone aceponate.]
[N06DX01, memantine, The therapeutic efficacy of Memantine can be decreased when used in combination with Methylprednisolone aceponate.]
[L02BG01, aminoglutethimide, The therapeutic efficacy of Methylprednisolone aceponate can be decreased when used in combination with Aminoglutethimide.]
[G03BB01, mesterolone, The risk or severity of edema formation can be increased when Mesterolone is combined with Methylprednisolone aceponate.]
[A10BA02, metformin, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Metformin.]
[A14AA04, methenolone, The risk or severity of edema formation can be increased when Metenolone is combined with Methylprednisolone aceponate.]
[C03AA08, methyclothiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone aceponate is combined with Methyclothiazide.]
[G03EK01, methyltestosterone, The risk or severity of edema formation can be increased when Methyltestosterone is combined with Methylprednisolone aceponate.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Methylprednisolone aceponate.]
[C03BA08, metolazone, Methylprednisolone aceponate may increase the hypokalemic activities of Metolazone.]
[N02BB03, aminopyrine, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Aminophenazone.]
[G03XB01, mifepristone, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Mifepristone.]
[L01XX23, mitotane, The serum concentration of Methylprednisolone aceponate can be decreased when it is combined with Mitotane.]
[M03AC03, vecuronium, The risk or severity of myopathy and weakness can be increased when Vecuronium is combined with Methylprednisolone aceponate.]
[N03AB05, fosphenytoin, The serum concentration of Methylprednisolone aceponate can be decreased when it is combined with Fosphenytoin.]
[S01XA11, nandrolone, The risk or severity of edema formation can be increased when Nandrolone phenpropionate is combined with Methylprednisolone aceponate.]
[M02AA12, naproxen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Naproxen.]
[A10BG01, troglitazone, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Troglitazone.]
[A10BX02, repaglinide, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Repaglinide.]
[S01EB06, neostigmine, The therapeutic efficacy of Neostigmine can be decreased when used in combination with Methylprednisolone aceponate.]
[J02AA01, amphotericin B, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Amphotericin B.]
[H05BX02, paricalcitol, The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Methylprednisolone aceponate.]
[M02AA17, niflumic acid, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Niflumic acid.]
[C01CA03, norepinephrine, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Norepinephrine.]
[G03DC02, norethindrone, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Norethisterone.]
[S01AE02, norfloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Norfloxacin.]
[G03AC07, norgestrienone, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Norgestrienone.]
[S02AA16, ofloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Ofloxacin.]
[R03CB03, metaproterenol, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Orciprenaline.]
[A14AA08, oxandrolone, The risk or severity of fluid retention can be increased when Methylprednisolone aceponate is combined with Oxandrolone.]
[J01MB05, oxolinic acid, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Oxolinic acid.]
[A14AA05, oxymetholone, The risk or severity of fluid retention can be increased when Methylprednisolone aceponate is combined with Oxymetholone.]
[S01BC02, oxyphenbutazone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Oxyphenbutazone.]
[M03AC01, pancuronium, The therapeutic efficacy of Pancuronium can be decreased when used in combination with Methylprednisolone aceponate.]
[G03DB06, chlormadinone, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Chlormadinone.]
[J01MA03, pefloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Pefloxacin.]
[A10BA01, phenformin, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Phenformin.]
[B01AA02, phenindione, Methylprednisolone aceponate may increase the anticoagulant activities of Phenindione.]
[B01AA04, phenprocoumon, Methylprednisolone aceponate may increase the anticoagulant activities of Phenprocoumon.]
[M02AA01, phenylbutazone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Phenylbutazone.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Methylprednisolone aceponate is combined with Phenylephrine.]
[R01BA01, phenylpropanolamine, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Phenylpropanolamine.]
[N03AB02, phenytoin, The serum concentration of Methylprednisolone aceponate can be decreased when it is combined with Phenytoin.]
[S01AE05, levofloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Levofloxacin.]
[V03AB19, physostigmine, The therapeutic efficacy of Physostigmine can be decreased when used in combination with Methylprednisolone aceponate.]
[S01BC06, piroxicam, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Piroxicam.]
[J01MA11, grepafloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Grepafloxacin.]
[A10BG02, rosiglitazone, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Rosiglitazone.]
[C03AA05, polythiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone aceponate is combined with Polythiazide.]
[A10BH03, saxagliptin, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Saxagliptin.]
[A10AD04, insulin lispro, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Insulin lispro.]
[C01BA02, procainamide, The therapeutic efficacy of Procainamide can be decreased when used in combination with Methylprednisolone aceponate.]
[S01HA05, procaine, The therapeutic efficacy of Procaine can be decreased when used in combination with Methylprednisolone aceponate.]
[G03DA04, progesterone, The serum concentration of Methylprednisolone aceponate can be increased when it is combined with Progesterone.]
[P02CC01, pyrantel, The risk or severity of myopathy and weakness can be increased when Pyrantel is combined with Methylprednisolone aceponate.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Methylprednisolone aceponate.]
[P01BC01, quinine, The risk or severity of hyperglycemia can be increased when Methylprednisolone aceponate is combined with Quinine.]
[G02CA01, ritodrine, The risk or severity of hypokalemia can be increased when Methylprednisolone aceponate is combined with Ritodrine.]
[N02BA05, salicylamide, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone aceponate is combined with Salicylic acid.]
[P02BB01, trichlorfon, The therapeutic efficacy of Metrifonate can be decreased when used in combination with Methylprednisolone.]
[S02DA03, antipyrine, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Antipyrine.]
[A14AA02, stanozolol, The risk or severity of fluid retention can be increased when Methylprednisolone is combined with Stanozolol.]
[G03XB02, ulipristal, The serum concentration of Methylprednisolone can be increased when it is combined with Ulipristal.]
[L04AA04, rabbit anti-human T-lymphocyte globulin, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Methylprednisolone.]
[L01AD04, streptozocin, The risk or severity of adverse effects can be increased when Streptozocin is combined with Methylprednisolone.]
[L04AA27, fingolimod, Methylprednisolone may increase the immunosuppressive activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of myopathy and weakness can be increased when Succinylcholine is combined with Methylprednisolone.]
[J01EC02, sulfadiazine, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Sulfadiazine.]
[J01EC01, sulfamethoxazole, The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Methylprednisolone.]
[S01AB02, sulfisoxazole, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Sulfisoxazole.]
[M01AB02, sulindac, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Sulindac.]
[N05AL01, sulpiride, The therapeutic efficacy of Sulpiride can be decreased when used in combination with Methylprednisolone.]
[A10BB04, glibornuride, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Glibornuride.]
[A10BC01, glymidine, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Glymidine.]
[M01AX04, apazone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Azapropazone.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mercaptopurine.]
[N06DA01, tacrine, The therapeutic efficacy of Tacrine can be decreased when used in combination with Methylprednisolone.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be increased when combined with Methylprednisolone.]
[L01CB02, teniposide, The metabolism of Teniposide can be increased when combined with Methylprednisolone.]
[R03CC03, terbutaline, The therapeutic efficacy of Terbutaline can be decreased when used in combination with Methylprednisolone.]
[G03BA03, testosterone, The risk or severity of edema formation can be increased when Testosterone is combined with Methylprednisolone.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Tetracaine.]
[L04AX02, thalidomide, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Thalidomide.]
[R03DA04, theophylline, The metabolism of Theophylline can be increased when combined with Methylprednisolone.]
[L01XX41, eribulin, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Eribulin.]
[L01AC01, thiotepa, The therapeutic efficacy of Thiotepa can be decreased when used in combination with Methylprednisolone.]
[L01BB03, thioguanine, The risk or severity of adverse effects can be increased when Tioguanine is combined with Methylprednisolone.]
[B02AB01, aprotinin, The therapeutic efficacy of Aprotinin can be decreased when used in combination with Methylprednisolone.]
[A10BB05, tolazamide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Tolazamide.]
[V04CA01, tolbutamide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Tolbutamide.]
[M02AA21, tolmetin, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Tolmetin.]
[N02AX02, tramadol, The metabolism of Tramadol can be increased when combined with Methylprednisolone.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Methylprednisolone.]
[S01BA05, triamcinolone, The risk or severity of adverse effects can be increased when Triamcinolone is combined with Methylprednisolone.]
[C03AA06, trichlormethiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone is combined with Trichlormethiazide.]
[S01EB04, demecarium, The therapeutic efficacy of Demecarium can be decreased when used in combination with Methylprednisolone.]
[S01AD02, trifluridine, The risk or severity of adverse effects can be increased when Trifluridine is combined with Methylprednisolone.]
[N05AA05, triflupromazine, The therapeutic efficacy of Triflupromazine can be decreased when used in combination with Methylprednisolone.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fluclorolone.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Methylprednisolone.]
[J01FA08, troleandomycin, The metabolism of Methylprednisolone can be decreased when combined with Troleandomycin.]
[M03AA02, tubocurarine, The therapeutic efficacy of Tubocurarine can be decreased when used in combination with Methylprednisolone.]
[R03DX07, roflumilast, Roflumilast may increase the immunosuppressive activities of Methylprednisolone.]
[L04AA26, belimumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Belimumab.]
[S01AA05, tyrothricin, The therapeutic efficacy of Tyrothricin can be decreased when used in combination with Methylprednisolone.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be increased when combined with Methylprednisolone.]
[A10BH05, linagliptin, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Methylprednisolone can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Methylprednisolone can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The serum concentration of Rilpivirine can be decreased when it is combined with Methylprednisolone.]
[L04AA28, belatacept, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Belatacept.]
[R03AC18, indacaterol, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Indacaterol.]
[C08DA01, verapamil, The metabolism of Methylprednisolone can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Methylprednisolone can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be increased when combined with Methylprednisolone.]
[L01CA02, vincristine, The metabolism of Vincristine can be increased when combined with Methylprednisolone.]
[L01CA03, vindesine, The metabolism of Vindesine can be increased when combined with Methylprednisolone.]
[B01AA03, warfarin, Methylprednisolone may increase the anticoagulant activities of Warfarin.]
[S01AA13, fusidic acid, The metabolism of Methylprednisolone can be decreased when combined with Fusidic acid.]
[J05AF01, zidovudine, The risk or severity of adverse effects can be increased when Zidovudine is combined with Methylprednisolone.]
[N05AF05, zuclopenthixol, The metabolism of Zuclopenthixol can be increased when combined with Methylprednisolone.]
[J05AE02, indinavir, The metabolism of Methylprednisolone can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be increased when combined with Methylprednisolone.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be increased when combined with Methylprednisolone.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be increased when combined with Methylprednisolone.]
[H05BX03, doxercalciferol, The therapeutic efficacy of Doxercalciferol can be decreased when used in combination with Methylprednisolone.]
[J01MA13, trovafloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The metabolism of Methylprednisolone can be decreased when combined with Ziprasidone.]
[G03AC10, drospirenone, The serum concentration of Methylprednisolone can be increased when it is combined with Drospirenone.]
[L04AA34, alemtuzumab, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Methylprednisolone.]
[N02BA01, aspirin, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be increased when combined with Methylprednisolone.]
[L03AB11, peginterferon alfa-2a, The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Methylprednisolone.]
[A11CC03, alfacalcidol, The therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Methylprednisolone.]
[L01FA01, rituximab, The risk or severity of adverse effects can be increased when Rituximab is combined with Methylprednisolone.]
[J02AC03, voriconazole, The serum concentration of Methylprednisolone can be increased when it is combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of myopathy and weakness can be increased when Atracurium is combined with Methylprednisolone.]
[L01EK01, axitinib, The metabolism of Axitinib can be increased when combined with Methylprednisolone.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Prednylidene.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Methylprednisolone.]
[L01BC07, azacitidine, The risk or severity of adverse effects can be increased when Azacitidine is combined with Methylprednisolone.]
[L04AX01, azathioprine, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Azathioprine.]
[L01BC05, gemcitabine, The risk or severity of adverse effects can be increased when Gemcitabine is combined with Methylprednisolone.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Methylprednisolone.]
[J07BK01, varicella-zoster virus vaccine live (Oka-Merck) strain, The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Methylprednisolone.]
[L01FX02, gemtuzumab ozogamicin, The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Methylprednisolone.]
[L01XG02, carfilzomib, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Methylprednisolone can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Methylprednisolone can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Methylprednisolone can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be increased when combined with Methylprednisolone.]
[L04AA31, teriflunomide, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Teriflunomide.]
[A02AA05, magnesium silicate, The bioavailability of Methylprednisolone can be decreased when combined with Magnesium silicate.]
[A02AC02, calcium silicate, The bioavailability of Methylprednisolone can be decreased when combined with Calcium silicate.]
[L04AA22, abetimus, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Abetimus.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Aldosterone.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be increased when combined with Methylprednisolone.]
[C01AA01, acetyldigitoxin, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Acetyldigitoxin.]
[J05AE04, nelfinavir, The metabolism of Methylprednisolone can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Bendamustine.]
[N06DA02, donepezil, The therapeutic efficacy of Donepezil can be decreased when used in combination with Methylprednisolone.]
[N03AX22, perampanel, The metabolism of Perampanel can be increased when combined with Methylprednisolone.]
[L04AA29, tofacitinib, Methylprednisolone may increase the immunosuppressive activities of Tofacitinib.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be increased when combined with Methylprednisolone.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be increased when combined with Methylprednisolone.]
[A10BH04, alogliptin, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Alogliptin.]
[A16AX09, glycerol phenylbutyrate, The therapeutic efficacy of Glycerol phenylbutyrate can be decreased when used in combination with Methylprednisolone.]
[C03AA01, bendroflumethiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone is combined with Bendroflumethiazide.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be increased when combined with Methylprednisolone.]
[N02BA10, benorilate, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Benorilate.]
[A10BK02, canagliflozin, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Canagliflozin.]
[L04AX07, dimethyl fumarate, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Dimethyl fumarate.]
[J01MA15, gemifloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Moxifloxacin.]
[A10AE05, insulin detemir, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin detemir.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Benzocaine.]
[A10BX05, pramlintide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Pramlintide.]
[M01AH01, celecoxib, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Celecoxib.]
[L04AA18, everolimus, The serum concentration of Methylprednisolone can be increased when it is combined with Everolimus.]
[L01EC02, dabrafenib, The serum concentration of Methylprednisolone can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The metabolism of Levomilnacipran can be increased when combined with Methylprednisolone.]
[A10BJ03, lixisenatide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Lixisenatide.]
[L01EL01, ibrutinib, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ibrutinib.]
[G03AC08, etonogestrel, The serum concentration of Methylprednisolone can be increased when it is combined with Etonogestrel.]
[J05AP05, simeprevir, The metabolism of Methylprednisolone can be decreased when combined with Simeprevir.]
[A10BK01, dapagliflozin, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Dapagliflozin.]
[C01CA27, droxidopa, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Droxidopa.]
[N05CH03, tasimelteon, The metabolism of Tasimelteon can be increased when combined with Methylprednisolone.]
[A16AA07, metreleptin, The metabolism of Methylprednisolone can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Apremilast.]
[L02BG02, formestane, The risk or severity of edema formation can be increased when Formestane is combined with Methylprednisolone.]
[A16AA06, betaine, The therapeutic efficacy of Betaine can be decreased when used in combination with Methylprednisolone.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Methylprednisolone.]
[A10BJ04, albiglutide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Albiglutide.]
[L04AC11, siltuximab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Ceritinib.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be increased when combined with Methylprednisolone.]
[L04AA33, vedolizumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Vedolizumab.]
[B01AA07, acenocoumarol, Methylprednisolone may increase the anticoagulant activities of Acenocoumarol.]
[L01XH04, belinostat, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Belinostat.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be increased when combined with Methylprednisolone.]
[A10BK03, empagliflozin, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Empagliflozin.]
[R03AC19, olodaterol, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Olodaterol.]
[L03AB13, peginterferon beta-1a, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Peginterferon beta-1a.]
[N05CM19, suvorexant, The metabolism of Suvorexant can be increased when combined with Methylprednisolone.]
[V04CX03, methacholine, Methylprednisolone may decrease effectiveness of Methacholine as a diagnostic agent.]
[A10BJ05, dulaglutide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Dulaglutide.]
[L01BC08, decitabine, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Decitabine.]
[L04AX05, pirfenidone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pirfenidone.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be increased when combined with Methylprednisolone.]
[L01FX07, blinatumomab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Blinatumomab.]
[L01XK01, olaparib, The metabolism of Olaparib can be increased when combined with Methylprednisolone.]
[B01AA01, dicumarol, Methylprednisolone may increase the anticoagulant activities of Dicoumarol.]
[L04AC10, secukinumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be increased when combined with Methylprednisolone.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be increased when combined with Methylprednisolone.]
[L01DC01, bleomycin, The risk or severity of adverse effects can be increased when Bleomycin is combined with Methylprednisolone.]
[B01AA11, tioclomarol, Methylprednisolone may increase the anticoagulant activities of Tioclomarol.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be increased when combined with Methylprednisolone.]
[A06AD03, magnesium peroxide, The bioavailability of Methylprednisolone can be decreased when combined with Magnesium peroxide.]
[A10BF01, acarbose, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Acarbose.]
[M02AA25, aceclofenac, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Aceclofenac.]
[M01AB11, acemetacin, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Acemetacin.]
[A10AE06, insulin degludec, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin degludec.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be increased when combined with Methylprednisolone.]
[R03DX09, mepolizumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mepolizumab.]
[J02AC05, isavuconazole, The metabolism of Methylprednisolone can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be increased when combined with Methylprednisolone.]
[J05AF13, tenofovir alafenamide, The metabolism of Tenofovir alafenamide can be increased when combined with Methylprednisolone.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be increased when combined with Methylprednisolone.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be increased when combined with Methylprednisolone.]
[L01ED03, alectinib, The metabolism of Alectinib can be increased when combined with Methylprednisolone.]
[A10BB31, acetohexamide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Acetohexamide.]
[M01AE16, alminoprofen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Alminoprofen.]
[A02AB06, aloglutamol, The bioavailability of Methylprednisolone can be decreased when combined with Aloglutamol.]
[N02BA02, aloxiprin, The serum concentration of Aloxiprin can be decreased when it is combined with Methylprednisolone.]
[L04AC13, ixekizumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ixekizumab.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be increased when combined with Methylprednisolone.]
[N04BC01, bromocriptine, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Bromocriptine.]
[A02AD05, aluminum magnesium silicate, The bioavailability of Methylprednisolone can be decreased when combined with Almasilate.]
[A02AB03, aluminum phosphate, The bioavailability of Methylprednisolone can be decreased when combined with Aluminium phosphate.]
[C08CA01, amlodipine, The metabolism of Amlodipine can be increased when combined with Methylprednisolone.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be increased when combined with Methylprednisolone.]
[C03CA02, bumetanide, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Bupivacaine.]
[L01AB01, busulfan, The metabolism of Busulfan can be increased when combined with Methylprednisolone.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, The therapeutic efficacy of Rivastigmine can be decreased when used in combination with Methylprednisolone.]
[J01MA09, sparfloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Sparfloxacin.]
[S01AA26, azithromycin, The serum concentration of Methylprednisolone can be increased when it is combined with Azithromycin.]
[L04AC12, brodalumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Brodalumab.]
[L01EF02, ribociclib, The metabolism of Methylprednisolone can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Balsalazide.]
[R03CC12, bambuterol, The therapeutic efficacy of Bambuterol can be decreased when used in combination with Methylprednisolone.]
[L04AA36, ocrelizumab, Ocrelizumab may increase the immunosuppressive activities of Methylprednisolone.]
[A10BX06, benfluorex, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Benfluorex.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Oxybuprocaine.]
[H05BX05, calcifediol, The therapeutic efficacy of Calcifediol can be decreased when used in combination with Methylprednisolone.]
[D05AX03, calcitriol, The therapeutic efficacy of Calcitriol can be decreased when used in combination with Methylprednisolone.]
[A12AA04, calcium carbonate, The bioavailability of Methylprednisolone can be decreased when combined with Calcium carbonate.]
[L04AC01, daclizumab, The risk or severity of adverse effects can be increased when Daclizumab is combined with Methylprednisolone.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Methylprednisolone.]
[J05AE09, tipranavir, The metabolism of Methylprednisolone can be decreased when combined with Tipranavir.]
[L04AB02, infliximab, The risk or severity of adverse effects can be increased when Infliximab is combined with Methylprednisolone.]
[L01EX10, midostaurin, The metabolism of Methylprednisolone can be decreased when combined with Midostaurin.]
[L01FF03, durvalumab, The therapeutic efficacy of Durvalumab can be decreased when used in combination with Methylprednisolone.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be increased when combined with Methylprednisolone.]
[L04AC14, sarilumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Sarilumab.]
[J01MA23, delafloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Delafloxacin.]
[L04AC16, guselkumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Guselkumab.]
[L01BC06, capecitabine, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Capecitabine.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be increased when combined with Methylprednisolone.]
[L01EH02, neratinib, The metabolism of Neratinib can be increased when combined with Methylprednisolone.]
[L01XH01, vorinostat, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be increased when combined with Methylprednisolone.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be increased when combined with Methylprednisolone.]
[R03AC17, bitolterol, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Bitolterol.]
[J05AG03, efavirenz, The metabolism of Methylprednisolone can be decreased when combined with Efavirenz.]
[L04AC02, basiliximab, The risk or severity of adverse effects can be increased when Basiliximab is combined with Methylprednisolone.]
[L01BA03, raltitrexed, The risk or severity of adverse effects can be increased when Raltitrexed is combined with Methylprednisolone.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Budesonide.]
[M01AB07, bumadizone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be increased when combined with Methylprednisolone.]
[C01AA02, acetyldigoxins, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Acetyldigoxin.]
[A10BJ06, semaglutide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Semaglutide.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Capsaicin.]
[A10BK04, ertugliflozin, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Ertugliflozin.]
[L02BB05, apalutamide, The metabolism of Methylprednisolone can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Carbamazepine can be increased when combined with Methylprednisolone.]
[L03AB06, interferon alfa-n1, The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Methylprednisolone.]
[L04AA37, baricitinib, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Baricitinib.]
[C07AB08, celiprolol, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Methylprednisolone can be increased when combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Methylprednisolone can be decreased when combined with Stiripentol.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be increased when combined with Methylprednisolone.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be increased when combined with Methylprednisolone.]
[A10BB06, carbutamide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Carbutamide.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Chloroprocaine.]
[M01AC05, lornoxicam, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Lornoxicam.]
[L04AA39, emapalumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Emapalumab.]
[L01AD01, carmustine, The risk or severity of adverse effects can be increased when Carmustine is combined with Methylprednisolone.]
[L01EX13, gilteritinib, The metabolism of Gilteritinib can be increased when combined with Methylprednisolone.]
[L04AA43, ravulizumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ravulizumab.]
[L04AA42, siponimod, The metabolism of Siponimod can be increased when combined with Methylprednisolone.]
[J01FA09, clarithromycin, The metabolism of Methylprednisolone can be decreased when combined with Clarithromycin.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be increased when combined with Methylprednisolone.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Cloprednol.]
[L04AB01, etanercept, The risk or severity of adverse effects can be increased when Etanercept is combined with Methylprednisolone.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Cortivazol.]
[L04AC18, risankizumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Risankizumab.]
[L01EM03, alpelisib, The metabolism of Alpelisib can be increased when combined with Methylprednisolone.]
[L01EX15, pexidartinib, The metabolism of Pexidartinib can be increased when combined with Methylprednisolone.]
[L04AA44, upadacitinib, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Upadacitinib.]
[L01EX14, entrectinib, The metabolism of Entrectinib can be increased when combined with Methylprednisolone.]
[N07XX11, pitolisant, The serum concentration of Methylprednisolone can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be increased when combined with Methylprednisolone.]
[J01XX12, lefamulin, The metabolism of Lefamulin can be increased when combined with Methylprednisolone.]
[C03AA09, cyclothiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone is combined with Cyclothiazide.]
[A10AE03, insulin, regular, pork, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin pork.]
[J01DB01, cephalexin, The metabolism of Cephalexin can be increased when combined with Methylprednisolone.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Deflazacort.]
[G03DB05, demegestone, The serum concentration of Methylprednisolone can be increased when it is combined with Demegestone.]
[L01FD01, trastuzumab, Trastuzumab may increase the neutropenic activities of Methylprednisolone.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be increased when combined with Methylprednisolone.]
[L04AX09, diroximel fumarate, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Diroximel fumarate.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be increased when combined with Methylprednisolone.]
[G03AC09, desogestrel, The serum concentration of Methylprednisolone can be increased when it is combined with Desogestrel.]
[N03AX25, cenobamate, The serum concentration of Methylprednisolone can be decreased when it is combined with Cenobamate.]
[S01XA12, dexpanthenol, The therapeutic efficacy of Dexpanthenol can be decreased when used in combination with Methylprednisolone.]
[N05CM21, lemborexant, The serum concentration of Lemborexant can be decreased when it is combined with Methylprednisolone.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be increased when combined with Methylprednisolone.]
[L04AA53, teprotumumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Teprotumumab.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be decreased when it is combined with Methylprednisolone.]
[N02CD06, rimegepant, The metabolism of Rimegepant can be increased when combined with Methylprednisolone.]
[S01AE06, gatifloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Gatifloxacin.]
[J05AE05, amprenavir, The metabolism of Methylprednisolone can be decreased when combined with Amprenavir.]
[L04AA38, ozanimod, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ozanimod.]
[G03DB08, dienogest, The serum concentration of Methylprednisolone can be increased when it is combined with Dienogest.]
[M01AH02, rofecoxib, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Rofecoxib.]
[L01XF03, bexarotene, The risk or severity of adverse effects can be increased when Bexarotene is combined with Methylprednisolone.]
[C01BD07, dronedarone, The metabolism of Dronedarone can be increased when combined with Methylprednisolone.]
[J01FA13, dirithromycin, The serum concentration of Methylprednisolone can be increased when it is combined with Dirithromycin.]
[L01AA02, chlorambucil, The risk or severity of adverse effects can be increased when Chlorambucil is combined with Methylprednisolone.]
[S03AA08, chloramphenicol, The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Methylprednisolone.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Methylprednisolone.]
[L01EX17, capmatinib, The serum concentration of Capmatinib can be decreased when it is combined with Methylprednisolone.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fluprednidene.]
[M01AC04, droxicam, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Droxicam.]
[L01EX22, selpercatinib, The serum concentration of Selpercatinib can be decreased when it is combined with Methylprednisolone.]
[M02AA27, dexketoprofen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Dexketoprofen.]
[L04AA47, inebilizumab, The risk or severity of infection can be increased when Methylprednisolone is combined with Inebilizumab.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Dyclonine.]
[R05CB11, stepronin, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Stepronin.]
[R06AX22, ebastine, The metabolism of Ebastine can be increased when combined with Methylprednisolone.]
[L04AC19, satralizumab, The serum concentration of Methylprednisolone can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The serum concentration of Oliceridine can be decreased when it is combined with Methylprednisolone.]
[C03AA04, chlorothiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone is combined with Chlorothiazide.]
[G03CA06, chlorotrianisene, The serum concentration of Methylprednisolone can be increased when it is combined with Chlorotrianisene.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Chlorpromazine can be decreased when used in combination with Methylprednisolone.]
[A10BB02, chlorpropamide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Chlorpropamide.]
[C03BA04, chlorthalidone, Methylprednisolone may increase the hypokalemic activities of Chlorthalidone.]
[A11CC05, cholecalciferol, The therapeutic efficacy of Cholecalciferol can be decreased when used in combination with Methylprednisolone.]
[N02BA07, ethenzamide, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Ethenzamide.]
[C10AC01, cholestyramine resin, Cholestyramine may increase the excretion rate of Methylprednisolone which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BA03, choline salicylate, The serum concentration of Choline salicylate can be decreased when it is combined with Methylprednisolone.]
[G03DC06, ethynodiol, The serum concentration of Methylprednisolone can be increased when it is combined with Etynodiol.]
[M01AB08, etodolac, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Etodolac.]
[M02AA06, etofenamate, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Methylprednisolone can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Methylprednisolone can be decreased when combined with Lonafarnib.]
[L01BB05, fludarabine, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fludarabine.]
[L04AD03, voclosporin, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Methylprednisolone can be increased when it is combined with Abametapir.]
[M01AE05, fenbufen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Fenbufen.]
[J01MB07, flumequine, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Flumequine.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Methylprednisolone.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Methylprednisolone.]
[R03CC15, formoterol, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Formoterol.]
[A10AF01, insulin, regular, human, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin human.]
[L04AA50, ponesimod, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ponesimod.]
[L01EK03, tivozanib, The metabolism of Tivozanib can be increased when combined with Methylprednisolone.]
[L03AB10, peginterferon alfa-2b, The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Methylprednisolone.]
[J01MB06, cinoxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Methylprednisolone can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be increased when combined with Methylprednisolone.]
[S03AA07, ciprofloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Ciprofloxacin.]
[L01XA01, cisplatin, The therapeutic efficacy of Cisplatin can be decreased when used in combination with Methylprednisolone.]
[L04AA54, pegcetacoplan, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pegcetacoplan.]
[L04AA48, belumosudil, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Belumosudil.]
[L04AA51, anifrolumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Anifrolumab.]
[M01AG01, mefenamic acid, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Mefenamic acid.]
[A10BB12, glimepiride, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Glimepiride.]
[A10BB08, gliquidone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Gliquidone.]
[R03CC13, clenbuterol, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Clenbuterol.]
[J01FF01, clindamycin, The metabolism of Clindamycin can be increased when combined with Methylprednisolone.]
[N06AX25, St. John's wort extract, The metabolism of Methylprednisolone can be increased when combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ropeginterferon alfa-2b.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Levobupivacaine.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be increased when combined with Methylprednisolone.]
[N03AE01, clonazepam, The metabolism of Clonazepam can be increased when combined with Methylprednisolone.]
[S01EA04, clonidine, The metabolism of Clonidine can be increased when combined with Methylprednisolone.]
[C01EB24, mavacamten, The serum concentration of Methylprednisolone can be decreased when it is combined with Mavacamten.]
[A10BX16, tirzepatide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Tirzepatide.]
[L04AC22, spesolimab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Spesolimab.]
[L04AA56, deucravacitinib, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Deucravacitinib.]
[N05AH02, clozapine, The metabolism of Methylprednisolone can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Guar gum.]
[A10BK06, sotagliflozin, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Sotagliflozin.]
[H01AC08, somatrogon, The metabolism of Methylprednisolone can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Cocaine.]
[L04AC21, bimekizumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Bimekizumab.]
[M01AX13, proquazone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Proquazone.]
[M03AC05, hexafluorenium, The therapeutic efficacy of Hexafluronium can be decreased when used in combination with Methylprednisolone.]
[L04AA13, leflunomide, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Leflunomide.]
[A02AD04, hydrotalcite, The bioavailability of Methylprednisolone can be decreased when combined with Hydrotalcite.]
[A10BX03, nateglinide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Nateglinide.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Imidazole salicylate.]
[H01AC03, mecasermin, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Mecasermin.]
[L01BB07, nelarabine, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Nelarabine.]
[A10AE04, insulin glargine, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin glargine.]
[J01FA15, telithromycin, The metabolism of Methylprednisolone can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ciclesonide.]
[B01AC10, indobufen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Indobufen.]
[M01AH03, valdecoxib, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Valdecoxib.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Methylprednisolone.]
[C01AA06, lanatoside C, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Lanatoside C.]
[M01AH04, parecoxib, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Methylprednisolone can be decreased when combined with Itraconazole.]
[M01AA06, kebuzone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Kebuzone.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Imatinib is combined with Methylprednisolone.]
[J02AC04, posaconazole, The metabolism of Methylprednisolone can be decreased when combined with Posaconazole.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Methylprednisolone.]
[S01AE04, lomefloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Lomefloxacin.]
[M01AB09, lonazolac, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Lonazolac.]
[M02AA31, loxoprofen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Loxoprofen.]
[A02AD02, magaldrate, The bioavailability of Methylprednisolone can be decreased when combined with Magaldrate.]
[A06AD01, magnesium carbonate, The bioavailability of Methylprednisolone can be decreased when combined with Magnesium carbonate.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Meprednisone.]
[L04AA15, alefacept, The risk or severity of adverse effects can be increased when Alefacept is combined with Methylprednisolone.]
[C03AA07, cyclopenthiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone is combined with Cyclopenthiazide.]
[J01FA03, midecamycin, The serum concentration of Methylprednisolone can be increased when it is combined with Midecamycin.]
[A10BF02, miglitol, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Miglitol.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be increased when combined with Methylprednisolone.]
[N06AX07, minaprine, The therapeutic efficacy of Minaprine can be decreased when used in combination with Methylprednisolone.]
[S01XA18, cyclosporine, The serum concentration of Methylprednisolone can be increased when it is combined with Cyclosporine.]
[C10AA07, rosuvastatin, The metabolism of Rosuvastatin can be increased when combined with Methylprednisolone.]
[M02AA02, mofebutazone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Mofebutazone.]
[M01AX22, morniflumate, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Methylprednisolone can be decreased when combined with Conivaptan.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Cytarabine.]
[M01AH05, etoricoxib, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Etoricoxib.]
[L01AX04, dacarbazine, The risk or severity of adverse effects can be increased when Dacarbazine is combined with Methylprednisolone.]
[L01DA01, dactinomycin, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Dactinomycin.]
[G03XA01, danazol, The metabolism of Methylprednisolone can be decreased when combined with Danazol.]
[L01DB02, daunorubicin, The risk or severity of adverse effects can be increased when Daunorubicin is combined with Methylprednisolone.]
[M01AX01, nabumetone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Nabumetone.]
[N06AX06, nefazodone, The metabolism of Methylprednisolone can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, The risk or severity of ulceration can be increased when Methylprednisolone is combined with Nicorandil.]
[G03DB04, nomegestrol, The serum concentration of Methylprednisolone can be increased when it is combined with Nomegestrol.]
[M03AC11, cisatracurium, The risk or severity of myopathy and weakness can be increased when Cisatracurium is combined with Methylprednisolone.]
[D11AH02, pimecrolimus, The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Methylprednisolone.]
[A07EC03, olsalazine, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Olsalazine.]
[C01AA07, deslanoside, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Deslanoside.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Methylprednisolone.]
[L01XA03, oxaliplatin, The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Methylprednisolone.]
[M01AE12, oxaprozin, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Oxaprozin.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Dexamethasone.]
[L04AB04, adalimumab, The risk or severity of adverse effects can be increased when Adalimumab is combined with Methylprednisolone.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Cinchocaine.]
[S01BC03, diclofenac, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Diclofenac.]
[G03CC02, dienestrol, The serum concentration of Methylprednisolone can be increased when it is combined with Dienestrol.]
[A10BG03, pioglitazone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Pioglitazone.]
[L01DC04, ixabepilone, The serum concentration of Methylprednisolone can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The serum concentration of Erlotinib can be decreased when it is combined with Methylprednisolone.]
[L01DB08, pirarubicin, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pirarubicin.]
[R03CC07, pirbuterol, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Pirbuterol.]
[C03CA03, piretanide, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Piretanide.]
[P02CB02, diethylcarbamazine, The therapeutic efficacy of Diethylcarbamazine can be decreased when used in combination with Methylprednisolone.]
[L02AA01, diethylstilbestrol, The serum concentration of Methylprednisolone can be increased when it is combined with Diethylstilbestrol.]
[C08CA03, isradipine, The metabolism of Methylprednisolone can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Difluocortolone.]
[N02BA11, diflunisal, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Diflunisal.]
[C01AA04, digitoxin, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Digitoxin.]
[C01AA05, digoxin, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Digoxin.]
[L02AA02, polyestradiol phosphate, The serum concentration of Methylprednisolone can be increased when it is combined with Polyestradiol phosphate.]
[L01XX24, pegaspargase, The risk or severity of adverse effects can be increased when Pegaspargase is combined with Methylprednisolone.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be increased when combined with Methylprednisolone.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be increased when combined with Methylprednisolone.]
[L04AX04, lenalidomide, The risk or severity of adverse effects can be increased when Lenalidomide is combined with Methylprednisolone.]
[A11CC02, dihydrotachysterol, The therapeutic efficacy of Dihydrotachysterol can be decreased when used in combination with Methylprednisolone.]
[J05AE08, atazanavir, The metabolism of Methylprednisolone can be decreased when combined with Atazanavir.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Methylprednisolone can be decreased when combined with Diltiazem.]
[R03CC08, procaterol, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Procaterol.]
[G03CA09, promestriene, The serum concentration of Methylprednisolone can be increased when it is combined with Promestriene.]
[N02BB04, propyphenazone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Propyphenazone.]
[M01AB14, proglumetacin, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Proglumetacin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Proparacaine.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Diphenhydramine.]
[A03FA02, cisapride, The metabolism of Cisapride can be increased when combined with Methylprednisolone.]
[S01XA23, sirolimus, The serum concentration of Methylprednisolone can be increased when it is combined with Sirolimus.]
[C01BA03, disopyramide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Disopyramide.]
[L04AA23, natalizumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Natalizumab.]
[N07AA03, distigmine, The therapeutic efficacy of Distigmine can be decreased when used in combination with Methylprednisolone.]
[S02AA12, rifamycin SV, The metabolism of Methylprednisolone can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Methylprednisolone can be increased when combined with Rifapentine.]
[L04AA21, efalizumab, The risk or severity of adverse effects can be increased when Efalizumab is combined with Methylprednisolone.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Rosoxacin.]
[L01EX01, sunitinib, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Sunitinib.]
[A04AD12, aprepitant, The metabolism of Methylprednisolone can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be increased when combined with Methylprednisolone.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be increased when combined with Methylprednisolone.]
[S01BC05, ketorolac, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Ketorolac.]
[C01EB18, ranolazine, The metabolism of Ranolazine can be increased when combined with Methylprednisolone.]
[N02BA06, salsalate, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Salmeterol.]
[C01CA07, dobutamine, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Dobutamine.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be increased when combined with Methylprednisolone.]
[B05XA02, sodium bicarbonate, The bioavailability of Methylprednisolone can be decreased when combined with Sodium bicarbonate.]
[V04CX07, edrophonium, The therapeutic efficacy of Edrophonium can be decreased when used in combination with Methylprednisolone.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Corticotropin.]
[J01MA05, temafloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Temafloxacin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Temozolomide is combined with Methylprednisolone.]
[M01AC02, tenoxicam, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Tenoxicam.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be increased when combined with Methylprednisolone.]
[G03CX01, tibolone, The serum concentration of Methylprednisolone can be increased when it is combined with Tibolone.]
[M01AG02, tolfenamic acid, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Tolfenamic acid.]
[C03CA04, torsemide, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Torasemide.]
[H02CA01, trilostane, The risk or severity of edema formation can be increased when Trilostane is combined with Methylprednisolone.]
[L01AA07, trofosfamide, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Trofosfamide.]
[J01MA04, enoxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Enoxacin.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be increased when combined with Methylprednisolone.]
[S01FB02, ephedrine, Ephedrine may increase the excretion rate of Methylprednisolone which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA12, mepirodipine, The metabolism of Methylprednisolone can be decreased when combined with Barnidipine.]
[S01EA01, epinephrine, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Epinephrine.]
[L01DB03, epirubicin, The risk or severity of adverse effects can be increased when Epirubicin is combined with Methylprednisolone.]
[N05CF02, zolpidem, The metabolism of Zolpidem can be increased when combined with Methylprednisolone.]
[M01AB04, zomepirac, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Zomepirac.]
[A10AB06, insulin glulisine, human, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin glulisine.]
[L01XA02, carboplatin, The risk or severity of adverse effects can be increased when Carboplatin is combined with Methylprednisolone.]
[A11CC01, ergocalciferol, The therapeutic efficacy of Ergocalciferol can be decreased when used in combination with Methylprednisolone.]
[N02CA02, ergotamine, The metabolism of Methylprednisolone can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The serum concentration of Methylprednisolone can be increased when it is combined with Erythromycin.]
[G03CA03, estradiol, The serum concentration of Methylprednisolone can be increased when it is combined with Estradiol.]
[L01XX11, estramustine, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Estramustine.]
[G03CC06, estriol, The serum concentration of Methylprednisolone can be increased when it is combined with Estriol.]
[G03CA57, estrogens, conjugated (USP), The serum concentration of Methylprednisolone can be increased when it is combined with Conjugated estrogens.]
[G03CC04, estrone, The serum concentration of Methylprednisolone can be increased when it is combined with Estrone.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fluticasone.]
[L02AA03, ethinyl estradiol, The serum concentration of Methylprednisolone can be increased when it is combined with Ethinylestradiol.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Methylprednisolone.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Etidocaine.]
[L01CB01, etoposide, The metabolism of Etoposide can be increased when combined with Methylprednisolone.]
[L04AD02, tacrolimus, Tacrolimus may increase the immunosuppressive activities of Methylprednisolone.]
[A02BA04, nizatidine, The therapeutic efficacy of Nizatidine can be decreased when used in combination with Methylprednisolone.]
[J01MA08, fleroxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Astemizole can be increased when combined with Methylprednisolone.]
[R06AX12, terfenadine, The metabolism of Methylprednisolone can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Methylprednisolone can be decreased when combined with Fluvoxamine.]
[L04AA02, muromonab-CD3, The risk or severity of adverse effects can be increased when Muromonab is combined with Methylprednisolone.]
[V03AF02, dexrazoxane, The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Methylprednisolone.]
[P02CA03, albendazole, The metabolism of Albendazole can be increased when combined with Methylprednisolone.]
[M01AE04, fenoprofen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Fenoprofen.]
[R03CC04, fenoterol, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Fenoterol.]
[R03CC02, albuterol, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Salbutamol.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Methylprednisolone.]
[L04AA40, cladribine, The risk or severity of adverse effects can be increased when Cladribine is combined with Methylprednisolone.]
[N02BG04, floctafenine, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Methylprednisolone can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Flucytosine.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Methylprednisolone.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fluocinonide.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fluocortolone.]
[L01BC09, floxuridine, The risk or severity of adverse effects can be increased when Floxuridine is combined with Methylprednisolone.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Methylprednisolone.]
[L01BC02, fluorouracil, The risk or severity of adverse effects can be increased when Fluorouracil is combined with Methylprednisolone.]
[G03BA01, fluoxymesterone, The risk or severity of fluid retention can be increased when Methylprednisolone is combined with Fluoxymesterone.]
[S01BC04, flurbiprofen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Flurbiprofen.]
[M03AA01, alcuronium, The risk or severity of myopathy and weakness can be increased when Alcuronium is combined with Methylprednisolone.]
[J05AE10, darunavir, The metabolism of Methylprednisolone can be decreased when combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Furosemide.]
[N05CF04, eszopiclone, The serum concentration of Eszopiclone can be decreased when it is combined with Methylprednisolone.]
[N06DA04, galantamine, The therapeutic efficacy of Galantamine can be decreased when used in combination with Methylprednisolone.]
[M03AC02, gallamine, The risk or severity of myopathy and weakness can be increased when Gallamine is combined with Methylprednisolone.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be increased when combined with Methylprednisolone.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be increased when combined with Methylprednisolone.]
[A10BJ02, liraglutide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Liraglutide.]
[G03XA02, gestrinone, The serum concentration of Methylprednisolone can be increased when it is combined with Gestrinone.]
[A10BB01, glyburide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Glyburide.]
[A10BB09, gliclazide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Gliclazide.]
[A10BB07, glipizide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Glipizide.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be increased when combined with Methylprednisolone.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be increased when combined with Methylprednisolone.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be increased when combined with Methylprednisolone.]
[B01AA12, fluindione, Methylprednisolone may increase the anticoagulant activities of Fluindione.]
[N05AD01, haloperidol, The serum concentration of Haloperidol can be increased when it is combined with Methylprednisolone.]
[A10AD05, insulin aspart, human, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin aspart.]
[L01CE02, irinotecan, The metabolism of Irinotecan can be increased when combined with Methylprednisolone.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be increased when combined with Methylprednisolone.]
[A07EC02, mesalamine, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Mesalazine.]
[L01XX03, altretamine, The risk or severity of adverse effects can be increased when Altretamine is combined with Methylprednisolone.]
[R03CC05, hexoprenaline, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Hexoprenaline.]
[C08CA10, nilvadipine, The metabolism of Methylprednisolone can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Nimesulide.]
[C03AA03, hydrochlorothiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone is combined with Hydrochlorothiazide.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Hydrocortisone butyrate.]
[C03AA02, hydroflumethiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone is combined with Hydroflumethiazide.]
[P01BA02, hydroxychloroquine, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Hydroxychloroquine.]
[L01XX05, hydroxyurea, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Hydroxyurea.]
[R02AX02, ibuprofen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Ibuprofen.]
[L01DB06, idarubicin, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Idarubicin.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be increased when combined with Methylprednisolone.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be increased when combined with Methylprednisolone.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Tixocortol.]
[L01CE01, topotecan, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Topotecan.]
[C03BA11, indapamide, Methylprednisolone may increase the hypokalemic activities of Indapamide.]
[S01BC01, indomethacin, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Indomethacin.]
[L03AB04, interferon alfa-2a, The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Methylprednisolone.]
[L03AB05, interferon alfa-2b, The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Methylprednisolone.]
[N06AX17, milnacipran, The metabolism of Milnacipran can be increased when combined with Methylprednisolone.]
[L04AA25, eculizumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Eculizumab.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Articaine.]
[A10BH01, sitagliptin, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Sitagliptin.]
[A10BH02, vildagliptin, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Vildagliptin.]
[C03BA02, quinethazone, Methylprednisolone may increase the hypokalemic activities of Quinethazone.]
[L03AB09, interferon alfacon-1, The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Methylprednisolone.]
[R03CC06, isoetharine, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Isoetharine.]
[S01EB07, isoflurophate, The therapeutic efficacy of Isoflurophate can be decreased when used in combination with Methylprednisolone.]
[J04AC01, isoniazid, The serum concentration of Isoniazid can be decreased when it is combined with Methylprednisolone.]
[R03CB01, isoproterenol, The therapeutic efficacy of Isoprenaline can be decreased when used in combination with Methylprednisolone.]
[A10BJ01, exenatide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Exenatide.]
[J01FA07, josamycin, The serum concentration of Methylprednisolone can be increased when it is combined with Josamycin.]
[A02AB01, aluminum hydroxide, The bioavailability of Methylprednisolone can be decreased when combined with Aluminum hydroxide.]
[L04AC07, tocilizumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Tocilizumab.]
[N01AX03, ketamine, The therapeutic efficacy of Ketamine can be decreased when used in combination with Methylprednisolone.]
[J02AB02, ketoconazole, The metabolism of Methylprednisolone can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Methylprednisolone can be decreased when combined with Levoketoconazole.]
[M02AA10, ketoprofen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Ketoprofen.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal ulceration and gastrointestinal irritation can be increased when Methylprednisolone is combined with Deferasirox.]
[L04AA24, abatacept, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Abatacept.]
[C01CA22, arbutamine, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Arbutamine.]
[M01AE11, tiaprofenic acid, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Tiaprofenic acid.]
[N07AA30, ambenonium, The therapeutic efficacy of Ambenonium can be decreased when used in combination with Methylprednisolone.]
[N03AX18, lacosamide, The metabolism of Lacosamide can be increased when combined with Methylprednisolone.]
[C03CC01, ethacrynic acid, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Etacrynic acid.]
[L01DC03, mitomycin, The risk or severity of adverse effects can be increased when Mitomycin is combined with Methylprednisolone.]
[G03AD01, levonorgestrel, The serum concentration of Methylprednisolone can be increased when it is combined with Levonorgestrel.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be increased when combined with Methylprednisolone.]
[L01AD02, lomustine, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Lomustine.]
[C10AA02, lovastatin, The metabolism of Methylprednisolone can be decreased when combined with Lovastatin.]
[G03DC03, lynestrenol, The serum concentration of Methylprednisolone can be increased when it is combined with Lynestrenol.]
[L01EG01, temsirolimus, The serum concentration of Methylprednisolone can be increased when it is combined with Temsirolimus.]
[G04BX01, magnesium hydroxide, The bioavailability of Methylprednisolone can be decreased when combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The bioavailability of Methylprednisolone can be decreased when combined with Magnesium oxide.]
[L01BA05, pralatrexate, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Pralatrexate.]
[L01EA03, nilotinib, The metabolism of Methylprednisolone can be decreased when combined with Nilotinib.]
[L01AA05, mechlorethamine, The therapeutic efficacy of Mechlorethamine can be decreased when used in combination with Methylprednisolone.]
[M02AA18, meclofenamic acid, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Meclofenamic acid.]
[C01AA08, medigoxin, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Metildigoxin.]
[P01BC02, mefloquine, The therapeutic efficacy of Mefloquine can be decreased when used in combination with Methylprednisolone.]
[L01AA03, melphalan, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Melphalan.]
[N06DX01, memantine, The therapeutic efficacy of Memantine can be decreased when used in combination with Methylprednisolone.]
[N02AB02, meperidine, The metabolism of Meperidine can be increased when combined with Methylprednisolone.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Mepivacaine.]
[L02BG01, aminoglutethimide, The therapeutic efficacy of Methylprednisolone can be decreased when used in combination with Aminoglutethimide.]
[G03BB01, mesterolone, The risk or severity of edema formation can be increased when Mesterolone is combined with Methylprednisolone.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be decreased when used in combination with Methylprednisolone.]
[A14AA04, methenolone, The risk or severity of edema formation can be increased when Metenolone is combined with Methylprednisolone.]
[H03BB02, methimazole, The metabolism of Methylprednisolone can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The risk or severity of adverse effects can be increased when Pemetrexed is combined with Methylprednisolone.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be increased when combined with Methylprednisolone.]
[C03AA08, methyclothiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone is combined with Methyclothiazide.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be increased when combined with Methylprednisolone.]
[L04AA03, lymphocyte immune globulin, anti-thymocyte globulin, equine, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Antilymphocyte immunoglobulin (horse).]
[J01MB04, pipemidic acid, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Pipemidic acid.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Fluticasone furoate.]
[J01MB02, nalidixic acid, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Nalidixic acid.]
[G03EK01, methyltestosterone, The risk or severity of edema formation can be increased when Methyltestosterone is combined with Methylprednisolone.]
[N02CA04, methysergide, The metabolism of Methysergide can be increased when combined with Methylprednisolone.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Methylprednisolone.]
[C03BA08, metolazone, Methylprednisolone may increase the hypokalemic activities of Metolazone.]
[S02AA13, miconazole, The metabolism of Methylprednisolone can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Aminophenazone.]
[G03XB01, mifepristone, The serum concentration of Methylprednisolone can be increased when it is combined with Mifepristone.]
[J01FA11, miocamycin, The serum concentration of Methylprednisolone can be increased when it is combined with Miocamycin.]
[L01XX23, mitotane, The serum concentration of Methylprednisolone can be decreased when it is combined with Mitotane.]
[L01DB07, mitoxantrone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mitoxantrone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Methylprednisolone.]
[C01BD01, amiodarone, The metabolism of Methylprednisolone can be decreased when combined with Amiodarone.]
[L04AB05, certolizumab pegol, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Certolizumab pegol.]
[L04AA52, ofatumumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Ofatumumab.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be increased when combined with Methylprednisolone.]
[L04AA06, mycophenolic acid, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Mycophenolic acid.]
[M03AC03, vecuronium, The risk or severity of myopathy and weakness can be increased when Vecuronium is combined with Methylprednisolone.]
[N03AB05, fosphenytoin, The serum concentration of Methylprednisolone can be decreased when it is combined with Fosphenytoin.]
[L03AB08, interferon beta-1b, The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Methylprednisolone.]
[V03AB15, naloxone, The metabolism of Methylprednisolone can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The risk or severity of adverse effects can be increased when Anakinra is combined with Methylprednisolone.]
[S01XA11, nandrolone, The risk or severity of edema formation can be increased when Nandrolone phenpropionate is combined with Methylprednisolone.]
[M02AA12, naproxen, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Naproxen.]
[A10BG01, troglitazone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Troglitazone.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Methylprednisolone.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be increased when combined with Methylprednisolone.]
[A10BX02, repaglinide, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Repaglinide.]
[S01EB06, neostigmine, The therapeutic efficacy of Neostigmine can be decreased when used in combination with Methylprednisolone.]
[J02AA01, amphotericin B, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Amphotericin B.]
[N06AX23, desvenlafaxine, The metabolism of Methylprednisolone can be decreased when combined with Desvenlafaxine.]
[H05BX02, paricalcitol, The therapeutic efficacy of Paricalcitol can be decreased when used in combination with Methylprednisolone.]
[L01XX01, amsacrine, The risk or severity of adverse effects can be increased when Amsacrine is combined with Methylprednisolone.]
[C08CA04, nicardipine, The metabolism of Methylprednisolone can be decreased when combined with Nicardipine.]
[M02AA17, niflumic acid, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Niflumic acid.]
[C01CA03, norepinephrine, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Norepinephrine.]
[G03DC02, norethindrone, The serum concentration of Methylprednisolone can be increased when it is combined with Norethisterone.]
[S01AE02, norfloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Norfloxacin.]
[G03AC07, norgestrienone, The serum concentration of Methylprednisolone can be increased when it is combined with Norgestrienone.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be increased when combined with Methylprednisolone.]
[S02AA16, ofloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Ofloxacin.]
[J01FA05, oleandomycin, The serum concentration of Methylprednisolone can be increased when it is combined with Oleandomycin.]
[L04AC04, rilonacept, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Rilonacept.]
[R03CB03, metaproterenol, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Orciprenaline.]
[A14AA08, oxandrolone, The risk or severity of fluid retention can be increased when Methylprednisolone is combined with Oxandrolone.]
[J01MB05, oxolinic acid, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Oxolinic acid.]
[A14AA05, oxymetholone, The risk or severity of fluid retention can be increased when Methylprednisolone is combined with Oxymetholone.]
[S01BC02, oxyphenbutazone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Oxyphenbutazone.]
[J04AA01, aminosalicylic acid, The serum concentration of Aminosalicylic acid can be decreased when it is combined with Methylprednisolone.]
[M03AC01, pancuronium, The therapeutic efficacy of Pancuronium can be decreased when used in combination with Methylprednisolone.]
[G03DB06, chlormadinone, The serum concentration of Methylprednisolone can be increased when it is combined with Chlormadinone.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Paramethasone.]
[J01MA03, pefloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Pefloxacin.]
[M01CC01, penicillamine, The risk or severity of adverse effects can be increased when Penicillamine is combined with Methylprednisolone.]
[J07AF01, diphtheria toxoid vaccine, inactivated, The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Methylprednisolone.]
[J07AM01, tetanus toxoid vaccine, inactivated, The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Methylprednisolone.]
[N05CA01, pentobarbital, The metabolism of Methylprednisolone can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, The risk or severity of adverse effects can be increased when Pentostatin is combined with Methylprednisolone.]
[J07AJ, pertussis vaccine, The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Methylprednisolone.]
[A10BA01, phenformin, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Phenformin.]
[B01AA02, phenindione, Methylprednisolone may increase the anticoagulant activities of Phenindione.]
[N03AA02, phenobarbital, The metabolism of Methylprednisolone can be increased when combined with Phenobarbital.]
[B01AA04, phenprocoumon, Methylprednisolone may increase the anticoagulant activities of Phenprocoumon.]
[M02AA01, phenylbutazone, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Phenylbutazone.]
[S01GA05, phenylephrine, The risk or severity of hypertension can be increased when Methylprednisolone is combined with Phenylephrine.]
[R01BA01, phenylpropanolamine, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Phenylpropanolamine.]
[N03AB02, phenytoin, The serum concentration of Methylprednisolone can be decreased when it is combined with Phenytoin.]
[L04AB06, golimumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Levofloxacin.]
[V03AB19, physostigmine, The therapeutic efficacy of Physostigmine can be decreased when used in combination with Methylprednisolone.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be increased when combined with Methylprednisolone.]
[N05AG02, pimozide, The metabolism of Pimozide can be increased when combined with Methylprednisolone.]
[J05AE01, saquinavir, The metabolism of Methylprednisolone can be decreased when combined with Saquinavir.]
[S01BC06, piroxicam, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Piroxicam.]
[J01MA11, grepafloxacin, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Methylprednisolone can be decreased when combined with Delavirdine.]
[A10BG02, rosiglitazone, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Rosiglitazone.]
[L04AC08, canakinumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Canakinumab.]
[C03AA05, polythiazide, The risk or severity of electrolyte imbalance can be increased when Methylprednisolone is combined with Polythiazide.]
[J05AE03, ritonavir, The serum concentration of Methylprednisolone can be increased when it is combined with Ritonavir.]
[A10BH03, saxagliptin, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Saxagliptin.]
[A10AD04, insulin lispro, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Insulin lispro.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Methylprednisolone.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Methylprednisolone.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Prilocaine.]
[P01BA03, primaquine, The metabolism of Methylprednisolone can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Methylprednisolone can be increased when combined with Primidone.]
[C01BA02, procainamide, The therapeutic efficacy of Procainamide can be decreased when used in combination with Methylprednisolone.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Methylprednisolone is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Procarbazine.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be increased when combined with Methylprednisolone.]
[G03DA04, progesterone, The serum concentration of Methylprednisolone can be increased when it is combined with Progesterone.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be increased when combined with Methylprednisolone.]
[H03BA02, propylthiouracil, The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Methylprednisolone.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be increased when combined with Methylprednisolone.]
[P02CC01, pyrantel, The risk or severity of myopathy and weakness can be increased when Pyrantel is combined with Methylprednisolone.]
[J06BB05, rabies immune globulin, human, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Methylprednisolone.]
[N07AA02, pyridostigmine, The therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Methylprednisolone.]
[C01BA01, quinidine, The metabolism of Quinidine can be increased when combined with Methylprednisolone.]
[P01BC01, quinine, The risk or severity of hyperglycemia can be increased when Methylprednisolone is combined with Quinine.]
[J04AB02, rifampin, The metabolism of Methylprednisolone can be increased when combined with Rifampicin.]
[G02CA01, ritodrine, The risk or severity of hypokalemia can be increased when Methylprednisolone is combined with Ritodrine.]
[J01FA06, roxithromycin, The serum concentration of Methylprednisolone can be increased when it is combined with Roxithromycin.]
[N02BA05, salicylamide, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Salicylamide.]
[A07EC01, sulfasalazine, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The risk or severity of gastrointestinal irritation can be increased when Methylprednisolone is combined with Salicylic acid.]
[L01FA03, obinutuzumab, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Obinutuzumab.]
[M05BX04, denosumab, The risk or severity of adverse effects can be increased when Denosumab is combined with Methylprednisolone.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be increased when combined with Methylprednisolone.]
[L03AX17, sipuleucel-T, The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Methylprednisolone.]
[J01FA02, spiramycin, The serum concentration of Methylprednisolone can be increased when it is combined with Spiramycin.]
